Among Hispanic and Latino patients with peripheral artery disease 31% reported use of antiplatelet therapy, 26% reported use of lipid-lowering therapy, and 57% reported use of antihypertensive therapy in a new study.
When asked to elderly patients undergoing coronary artery calcium (CAC) scans, the results of a single question offer providers a better understanding of the individual’s risk of death: "On a scale of 1 - 10, how much do you exercise (0-none, 10-always)?"
The oral antiplatelet drug Ticagrelor (Brilinta, Astra Zeneca), was approved this week by the US Food and Drug Administration (FDA) for use in patients with coronary artery disease (CAD) who are at high risk for a first heart attack or stroke.
Patients with Medicare Advantage are more likely to receive guideline-recommended care for coronary artery disease than patients with Medicare Fee for Service. But whether that translates into better outcomes remains unclear, a study shows.